Downloading...
Download

ALLO

10 Small-Cap Biotechs with Key Catalysts for 2025 July List________________________________________ 🔬 10 Small-Cap Biotechs with Key Catalysts for 2025 July List ________________________________________ 1. Allogene Therapeutics (NASDAQ: ALLO) • Catalyst: Phase 2 data for ALLO-501A (anti-CD19 CAR-T for large B-cell lymphoma) expected in H2 2025; potential pivotal data could lead to regulatory submission. • Highlights: “Off-the-shelf” allogeneic CAR-T approach could transform cell therapy; watch for manufacturing/scalability updates. ________________________________________ 2. Lixte Biotechnology (NASDAQ: LIXT) • Catalyst: Phase 2 combo trial of LB-100 (PP2A inhibitor) + immunotherapy in solid tumors, with key data expected in late 2025. • Highlights: If efficacy signals emerge, could prompt partnerships or additional trials. ________________________________________ 3. Iovance Biotherapeutics (NASDAQ: IOVA) • Catalyst: Commercial launch and sales uptake for AMTAGVI (lifileucel, first FDA-approved TIL therapy in advanced melanoma); upcoming label expansion studies in lung and cervical cancer. • Highlights: Investor focus on launch ramp, real-world data, and new trial initiations in 2025. ________________________________________ 4. RenBio (NASDAQ: RENB) • Catalyst: Phase 1/2 data for RB-100 (bispecific antibody platform in solid tumors) expected mid-to-late 2025. • Highlights: Pipeline progress and partnership announcements possible. ________________________________________ 5. IGM Biosciences (NASDAQ: IGMS) • Catalyst: Phase 2 data for IGM-2323 (CD20 x CD3 bispecific in non-Hodgkin lymphoma) expected early 2025; ongoing updates from IgM antibody platform. • Highlights: Investor interest in clinical safety, efficacy, and potential for big pharma tie-ups. ________________________________________ 6. Zura Bio (NASDAQ: ZURA) • Catalyst: Phase 2b/3 trial start and topline data for tibulizumab (IL-7Ra mAb for autoimmune diseases) expected late 2025. • Highlights: Focus on rare and orphan autoimmune indications. ________________________________________ 7. INmune Bio (NASDAQ: INMB) • Catalyst: Phase 2 Alzheimer’s data (XPro1595, targeting neuroinflammation) and oncology pipeline updates expected H1 2025. • Highlights: Any signal in Alzheimer’s is high-impact; monitoring for FDA guidance. ________________________________________ 8. Veru Inc (NASDAQ: VERU) • Catalyst: Phase 3 trial results for enobosarm (oral SARM) in advanced breast cancer expected 2025; also, COVID/sepsis drug updates. • Highlights: Regulatory clarity and partnership/M&A rumors are potential drivers. ________________________________________ 9. Century Therapeutics (NASDAQ: IPSC) • Catalyst: First-in-human data for iPSC-derived NK and CAR-T cell therapies, with updates expected at major meetings in 2025. • Highlights: Platform validation and early efficacy/safety signals. ________________________________________ 10. ProKidney (NASDAQ: PROK) • Catalyst: Phase 3 pivotal data for REACT (cell therapy for chronic kidney disease/diabetes) due late 2025. • Highlights: If positive, could become the first autologous cell therapy for kidney disease. ________________________________________ 🔎 How to Monitor These Catalysts • FDA submissions/meetings (ALLO, PROK, VERU) • Clinical trial readouts (LIXT, RENB, IGMS, ZURA, INMB, IPSC) • Commercial/launch data (IOVA) • Partnership/M&A activity (IGMS, VERU, RENB) ________________________________________ 📊 Summary Table Ticker Company Upcoming Catalyst/Event Timeframe ALLO Allogene Therapeutics Phase 2 LBCL CAR-T pivotal data H2 2025 LIXT Lixte Biotechnology LB-100 + immunotherapy Phase 2 data Late 2025 IOVA Iovance Biotherapeutics AMTAGVI launch data; label expansions Throughout 2025 RENB RenBio Bispecifics Phase 1/2 data Mid-to-late 2025 IGMS IGM Biosciences IGM-2323 Phase 2 data (lymphoma) Early 2025 ZURA Zura Bio Tibulizumab Phase 2b/3 topline data Late 2025 INMB INmune Bio Alzheimer’s/oncology trial updates H1 2025 VERU Veru Inc Enobosarm Phase 3 (breast cancer) 2025 IPSC Century Therapeutics First-in-human iPSC cell therapy data 2025 PROK ProKidney REACT Phase 3 (CKD) pivotal readout Late 2025 ________________________________________ ⚠️ Word of Caution Small-cap biotech stocks can be extremely volatile, especially around catalyst events (trial data, FDA decisions). Sharp price swings—both up and down—are common. Always conduct your own research and be aware of the risks.
NASDAQ:IBBLong
by ProjectSyndicate
31
$RWA is ready for a massive 50% pump.About RWA:- Allo is building the world’s first exchange for tokenised stocks with 24/7 trading, low fees and instant settlement to democratize investing. Built on blockchain technology, Allo has tokenised $2.2B in RWAs, staked $50M in BTC, and launched a $100M lending facility. The fundamentals look good, and so does the chart. A massive breakout after 4 days of consolidation inside the channel. ENTRY :- .01150 .01240 Target:- 1390, 1477,1558,1623,1785 SL : 1020 Keep the leverage low. If you want me to post more setups like these, do show your support with a like. Thank you #PEACE
Long
by Cryptorphic
7
GOOD THINGS Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumor. "chimeric antigen receptor T (CAR-T) cells is said anti leukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). On May 13 2020 their stock chart value bearish $30.90. maybe because of this CORONA our pharmaceuticals focuses on developing COVID 19 kits but today their stock chart value is said hit $43.53 Anyone feel like it will potentially run more? Wanna Know more about BULLISH strategy READ MORE:
NASDAQ:ALLOLong
by bredragon
Bitcoin is “Clear for Liftoff” as Analysts Watch ForaMove HigherBitcoin is firmly caught within the throes of an immense uptrend. This was clearly seen yesterday when the cryptocurrency rallied up to highs of $10,000 before facing a slight rejection that led it lower. This was a massive $1,000 movement that marked a significant extension of the momentum that was first incurred when the crypto rebounded from its capitulatory decline to lows of $8,100. Because buyers ardently defended this level and have since provided BTC with sustained momentum, it does appear that it is well positioned to see further upside. One trader is now noting that Bitcoin looks “clear for liftoff” as it flashes signs of forming an immensely bullish market structure. Analysts believe this next movement could send it towards fresh yearly highs. Bitcoin Sees Notable Overnight Upswing as Analysts Watch for Further Gains At the time of writing, Bitcoin is trading up just under 7% at its current price of $9,700. Overnight BTC tapped highs of just under $10,000 before facing a slight rejection that led it into the mid-$9,000 region. This movement allowed it to firmly surmount all the heavy resistance it previously faced around $9,200 and $9,500. It is also important to keep in mind that this momentum marks a continuance of the macro uptrend that Bitcoin incurred in mid-March when it posted a “V-shaped recovery” from lows of $3,800. This recovery has also come about against a backdrop of global turbulence, as the stock market is beginning to flash signs of seeing another leg down as the global Coronavirus-induced lockdowns show few signs of letting up anytime soon. The benchmark cryptocurrency’s current strength could be enough to provide it with some significant momentum that provides it with further room to run. One popular pseudonymous analyst on Twitter spoke about this in a recent tweet, explaining that Bitcoin looks “clear for liftoff.” “Bitcoin weekly Heikin Ashi looks clear for liftoff,” he said while pointing to the chart. BTC Likely to Target Fresh Yearly Highs It is a strong possibility that the benchmark cryptocurrency will soon target fresh year-to-date highs as its technical strength begins mounting. These highs are currently established at $10,500, and this happens to be an important technical level that coincides closely with a descending trendline formed as a result of the crypto’s decline from highs of $13,800 in the summer months of 2019. Another popular trader recently explained that he expects BTC to test this key level in the days ahead, saying: “BTC access granted for bulls. Price trading above my bull trigger, let’s see if it holds. Above both the Monthly + Weekly S/R levels as well as the low time frame range high. Continue to hold above ~$9350 and I see us gunning for $10.5k.”
Long
by arlene_